Impact of smoking on lung cancer treatment effectiveness: a review-Reference-Cited by-同舟云学术

Impact of smoking on lung cancer treatment effectiveness: a review

Published:2016-09 Issue:18 Volume:12 Page:2149-2161
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Condoluci Adalgisa¹,Mazzara Calogero²,Zoccoli Alice²,Pezzuto Aldo³,Tonini Giuseppe²

Affiliation:

1. Thoracic Surgery Unit, San Giovanni Hospital, Bellinzona, Switzerland

2. Department of Oncology, University Campus Bio-Medico of Rome, Rome, Italy

3. Cardiovascular & Pulmonary Department, Sant'Andrea Hospital, Sapienza University, Rome, Italy

Abstract

Tobacco smoke contains more than 4000 detectable substances, such as polycyclic aromatic hydrocarbons, nicotine, carbon monoxide and heavy metals, which are considered powerful enzymatic inducers that have notable influence on the efficacy and tolerability of many medications through complex pharmacokinetic and pharmacodynamic interactions. As a result, adjustments of drug dosages are required in smokers, both if they continue to smoke or if they quit after smoking cessation treatment. The purpose of this review is to examine the main drug interactions with tobacco smoke clinically relevant, with a closer look on patients developing oncologic diseases.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2015-0055

Reference75 articles.

1. U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress: A Report of the Surgeon General. Atlanta, GA, USA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health (2014). http://ash.org/wp-content/uploads/2014/01/full-report.pdf.

2. More than 500 trillion molecules of strong carcinogens per cigarette: use in product labelling?

3. American Society of Clinical Oncology Policy Statement: The Role of the Oncologist in Cancer Prevention and Risk Assessment

4. New molecular insights in tobacco-induced lung cancer

5. Secondhand Tobacco Smoke Exposure and Lung Adenocarcinoma In Situ/Minimally Invasive Adenocarcinoma (AIS/MIA)

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of smoking status on health-related quality of life (HRQoL) in cancer survivors;Frontiers in Oncology;2024-01-04

2. Cluster Randomized Pragmatic Clinical Trial Testing Behavioral Economic Implementation Strategies to Improve Tobacco Treatment for Patients With Cancer Who Smoke;Journal of Clinical Oncology;2023-10-01

3. Smoking and quality of life in lung cancer patients: systematic review;BMJ Supportive & Palliative Care;2023-08-22

4. Effectiveness of smoking cessation on the high-risk population of lung cancer with early screening: a systematic review and meta-analysis of randomized controlled trials until January 2022;Archives of Public Health;2023-06-03

5. Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics;BMC Cancer;2023-05-19